AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16958285 — intervention group
Group type: EXPERIMENTAL
Intervention: CSEB + CRR + R
Number of subjects: 30
Study 16958285 — intervention group
Group type: COMPARATOR
Intervention: PBNT + CRR
Number of subjects: 30
Study 16958285 — intervention group
Group type: COMPARATOR
Intervention: CSEB + CRR
Number of subjects: 30
Study 15304585 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan 100 mg
Number of subjects: 3706
Study 15304585 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3706
Study 10890285 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone survey (DAT group)
Number of subjects: 126966
Study 10890285 — intervention group
Group type: COMPARATOR
Intervention: Mail survey (AT group)
Number of subjects: 126966
Study 10890285 — intervention group
Group type: COMPARATOR
Intervention: AT group (compared to DAT group)
Number of subjects: 126966
Study 10890285 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (DAT and AT)
Number of subjects: 126966
Study 10890285 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone survey (both groups)
Number of subjects: 126966
Study 10890285 — intervention group
Group type: COMPARATOR
Intervention: AT group (late response)
Number of subjects: 126966
Study 8677870 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol and nifedipine
Number of subjects: 235
Study 8677870 — intervention group
Group type: COMPARATOR
Intervention: Diltiazem and isosorbide dinitrate
Number of subjects: 235
Study 8677870 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 235
Study 2064065 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar epidural morphine 5 mg
Number of subjects: 15
Study 2064065 — intervention group
Group type: COMPARATOR
Intervention: Lumbar epidural nalbuphine 10 mg
Number of subjects: 15
Study 2064065 — intervention group
Group type: COMPARATOR
Intervention: Lumbar epidural nalbuphine 20 mg
Number of subjects: 15
Study 6321426 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem with cilastatin, 500 mg/500 mg iv tid
Number of subjects: 40
Study 6321426 — intervention group
Group type: COMPARATOR
Intervention: Cefotaxime, 2 g iv tid
Number of subjects: 40
Study 30564847 — intervention group
Group type: EXPERIMENTAL
Intervention: Paravertebral block (Pv, n=20) with 20 ml 0.25% bupivacaine at the level of T8-T9
Number of subjects: 60
Study 30564847 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritubal infiltration (Pi, n=20) with 20 ml 0.25% bupivacaine along the nephrostomy tube
Number of subjects: 60
Study 30564847 — intervention group
Group type: COMPARATOR
Intervention: Control group (C, n=20): no intervention
Number of subjects: 60
Study 30339623 — intervention group
Group type: EXPERIMENTAL
Intervention: Patch repair (PROCEED Ventral Patch)
Number of subjects: 352
Study 30339623 — intervention group
Group type: COMPARATOR
Intervention: Polypropylene mesh repair
Number of subjects: 352
Study 28472642 — intervention group
Group type: EXPERIMENTAL
Intervention: Seasoned vegetables (SS)
Number of subjects: 335
Study 28472642 — intervention group
Group type: COMPARATOR
Intervention: Steamed vegetables (ST)
Number of subjects: 335
Study 25259404 — intervention group
Group type: EXPERIMENTAL
Intervention: Inferior conjunctival autografting (ICA)
Number of subjects: 80
Study 25259404 — intervention group
Group type: COMPARATOR
Intervention: Superior conjunctival autografting (SCA)
Number of subjects: 80
Study 23380218 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg/d
Number of subjects: 1019
Study 23380218 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone 250 μg twice daily
Number of subjects: 1019
Study 23380218 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1019
Study 21211684 — intervention group
Group type: EXPERIMENTAL
Intervention: Years of education >16 years
Number of subjects: 11326
Study 21211684 — intervention group
Group type: COMPARATOR
Intervention: Years of education <8 years
Number of subjects: 11326
Study 21211684 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in years of education (per year)
Number of subjects: 11326
Study 19230906 — intervention group
Group type: EXPERIMENTAL
Intervention: Bubble CPAP
Number of subjects: 140
Study 19230906 — intervention group
Group type: COMPARATOR
Intervention: IFD CPAP
Number of subjects: 140
Study 16563995 — intervention group
Group type: EXPERIMENTAL
Intervention: PHDRB (4 Gy b.i.d. x 8 for R0 resections and 4 Gy b.i.d. x 10 for R1 resections)
Number of subjects: 25
Study 16563995 — intervention group
Group type: EXPERIMENTAL
Intervention: PHDRB
Number of subjects: 25
Study 15619331 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailor-made treatment program addressing biopsychosocial factors
Number of subjects: 0
Study 15619331 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 10620554 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant tissue plasminogen activator (rTPA) 2 mg
Number of subjects: 12
Study 10620554 — intervention group
Group type: COMPARATOR
Intervention: Heparin 2,000 IU
Number of subjects: 12
Study 8648870 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 536
Study 8648870 — intervention group
Group type: COMPARATOR
Intervention: Tricyclic antidepressants (imipramine or desipramine)
Number of subjects: 536
Study 8648870 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine, Tricyclic antidepressants
Number of subjects: 536
Study 1335647 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis A vaccine (720 ELISA units)
Number of subjects: 165
Study 1335647 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine (20 micrograms)
Number of subjects: 165
Study 1335647 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous administration of hepatitis A and B vaccines
Number of subjects: 165
Study 6100260 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (50 mg dose)
Number of subjects: 13
Study 6100260 — intervention group
Group type: COMPARATOR
Intervention: Control group (no drug administration)
Number of subjects: 13
Study 3033966 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral morphine (30 mg slow-release preparation)
Number of subjects: 20
Study 3033966 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (4 mg bolus iv)
Number of subjects: 20
Study 3033966 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (4 mg iv bolus followed by continuous infusion of 6 mg over 75 min)
Number of subjects: 20
Study 3033966 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for both morphine and naloxone protocols)
Number of subjects: 20
Study 29890806 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupotomy stress position percutaneous dynamic release
Number of subjects: 160
Study 29890806 — intervention group
Group type: COMPARATOR
Intervention: Simple joint loosening according to Maitland technique (control group)
Number of subjects: 160
Study 27590255 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual feedback on step-counts
Number of subjects: 165
Study 27590255 — intervention group
Group type: EXPERIMENTAL
Intervention: Social feedback comparing step-counts against others
Number of subjects: 165
Study 27590255 — intervention group
Group type: COMPARATOR
Intervention: No feedback (control)
Number of subjects: 165
Study 25622666 — intervention group
Group type: EXPERIMENTAL
Intervention: 270 mgI/ml low concentrations of contrast agents and spectral CT imaging (Group A)
Number of subjects: 160
Study 25622666 — intervention group
Group type: COMPARATOR
Intervention: 350 mgI/ml high concentrations of contrast agents and 120 kVp scan (Group B)
Number of subjects: 160
Study 25622666 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal keV images (Group C)
Number of subjects: 160
Study 23615823 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccination
Number of subjects: 40
Study 23615823 — intervention group
Group type: COMPARATOR
Intervention: Sham vaccination
Number of subjects: 40
Study 23615823 — intervention group
Group type: EXPERIMENTAL
Intervention: High cardiorespiratory fitness group
Number of subjects: 40
Study 23615823 — intervention group
Group type: EXPERIMENTAL
Intervention: Low cardiorespiratory fitness group
Number of subjects: 40
Study 20215126 — intervention group
Group type: EXPERIMENTAL
Intervention: CFE ablation alone (n = 34)
Number of subjects: 100
Study 20215126 — intervention group
Group type: EXPERIMENTAL
Intervention: PVI ablation alone (n = 32)
Number of subjects: 100
Study 20215126 — intervention group
Group type: EXPERIMENTAL
Intervention: PVI + CFE ablation (n = 34)
Number of subjects: 100
Study 20215126 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 100
Study 18721899 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose fish oil (9600 mg of fish oil/day, 2880 mg of n-3 fatty acids)
Number of subjects: 11
Study 16943516 — intervention group
Group type: EXPERIMENTAL
Intervention: Method 1 (highest interexaminer reliability)
Number of subjects: 24
Study 16943516 — intervention group
Group type: EXPERIMENTAL
Intervention: Method 2 (at least one test result abnormal)
Number of subjects: 24
Study 16943516 — intervention group
Group type: EXPERIMENTAL
Intervention: Method 3 (all test results abnormal)
Number of subjects: 24
Study 14576512 — intervention group
Group type: EXPERIMENTAL
Intervention: hANP (initial dose: 0.025 microg/kg/min, maximum dose: 0.035 +/- 0.019 microg/kg/min)
Number of subjects: 50
Study 14576512 — intervention group
Group type: EXPERIMENTAL
Intervention: hANP
Number of subjects: 50
Study 14576512 — intervention group
Group type: COMPARATOR
Intervention: Control (nicardipine hydrochloride; 4.41 +/- 1.68 mg/h)
Number of subjects: 50
Study 11109234 — intervention group
Group type: EXPERIMENTAL
Intervention: Arousal (D) cluster of symptoms
Number of subjects: 0
Study 11109234 — intervention group
Group type: COMPARATOR
Intervention: Physiological indices of arousal and reactivity
Number of subjects: 0
Study 8677571 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant MVAC chemotherapy
Number of subjects: 95
Study 8677571 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant MVAC chemotherapy
Number of subjects: 95
Study 2072368 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem 90 mg twice daily
Number of subjects: 115
Study 2072368 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol 100 mg once daily
Number of subjects: 115
Study 6353623 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin
Number of subjects: 60
Study 6353623 — intervention group
Group type: COMPARATOR
Intervention: Cefoxitin
Number of subjects: 60
Study 30871785 — intervention group
Group type: EXPERIMENTAL
Intervention: Self‐observation of the Body (SoB) training
Number of subjects: 0
Study 30871785 — intervention group
Group type: COMPARATOR
Intervention: Mental Monitoring (MM) training
Number of subjects: 0
Study 29189967 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized nursing intervention consisting of an in-person supportive care assessment with ongoing support to meet identified needs, including linkage to community services.
Number of subjects: 193
Study 29189967 — intervention group
Group type: COMPARATOR
Intervention: Usual care practices (Control group).
Number of subjects: 193
Study 27059799 — intervention group
Group type: EXPERIMENTAL
Intervention: Clazakizumab 100 mg
Number of subjects: 165
Study 27059799 — intervention group
Group type: EXPERIMENTAL
Intervention: Clazakizumab 25 mg
Number of subjects: 165
Study 27059799 — intervention group
Group type: EXPERIMENTAL
Intervention: Clazakizumab 200 mg
Number of subjects: 165
Study 27059799 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 165
Study 27059799 — intervention group
Group type: EXPERIMENTAL
Intervention: Clazakizumab (all doses)
Number of subjects: 165
Study 27059799 — intervention group
Group type: EXPERIMENTAL
Intervention: Clazakizumab
Number of subjects: 165
Study 24697794 — intervention group
Group type: EXPERIMENTAL
Intervention: Full dental arch (RPDs with artificial molars)
Number of subjects: 11
Study 24697794 — intervention group
Group type: COMPARATOR
Intervention: Shortened dental arch (RPDs lacking artificial molars)
Number of subjects: 11
Study 22507276 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-strain combination probiotic (Lactobacillus acidophilus and Bifidobacterium bifidum) given twice a day for 3 months
Number of subjects: 80
Study 22507276 — intervention group
Group type: COMPARATOR
Intervention: Placebo given twice a day for 3 months
Number of subjects: 80
Study 22507276 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-strain combination probiotic
Number of subjects: 80
Study 22507276 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 20562586 — intervention group
Group type: EXPERIMENTAL
Intervention: T. vaginalis infection
Number of subjects: 0
Study 20562586 — intervention group
Group type: COMPARATOR
Intervention: HIV infection
Number of subjects: 0
Study 18628618 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg/day) for 14 days
Number of subjects: 22
Study 18628618 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine (500 microM)
Number of subjects: 22
Study 18628618 — intervention group
Group type: COMPARATOR
Intervention: L-N(5)-(I-iminoethyl)ornithine (NOS inhibitor)
Number of subjects: 22
Study 18628618 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet eNOS mRNA and protein levels
Number of subjects: 22
Study 15769245 — intervention group
Group type: EXPERIMENTAL
Intervention: Advantage in BATNA (Better Alternative to a Negotiated Agreement)
Number of subjects: 0
Study 15769245 — intervention group
Group type: EXPERIMENTAL
Intervention: Advantage in contributions
Number of subjects: 0
Study 11315826 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretic (chlorthalidone)
Number of subjects: 15297
Study 11315826 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium channel blocker (amlodipine)
Number of subjects: 15297
Study 11315826 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitor (lisinopril)
Number of subjects: 15297
Study 11315826 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-adrenergic blocker (doxazosin)
Number of subjects: 15297
Study 9326656 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral pyrimidine nucleoside or nucleotide compounds
Number of subjects: 4
Study 9326656 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study 7868871 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 13
Study 7868871 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 13
Study 3061422 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam alone
Number of subjects: 100
Study 3061422 — intervention group
Group type: COMPARATOR
Intervention: Diazepam with pethidine
Number of subjects: 100
Study 30528654 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple sessions of multisite transcranial random noise stimulation
Number of subjects: 29
Study 30528654 — intervention group
Group type: COMPARATOR
Intervention: Single session of multisite transcranial random noise stimulation
Number of subjects: 29
Study 28302288 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban
Number of subjects: 2824
Study 28302288 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 2824
Study 25692257 — intervention group
Group type: EXPERIMENTAL
Intervention: Syndecan-1 (S1) levels measured at admission and after one day
Number of subjects: 184
Study 25692257 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycosaminoglycan heparan sulfate levels measured at admission and after one day
Number of subjects: 184
Study 25692257 — intervention group
Group type: EXPERIMENTAL
Intervention: Admission S1 levels in survivors vs non-survivors at 30 days
Number of subjects: 184
Study 25692257 — intervention group
Group type: EXPERIMENTAL
Intervention: S1 as an independent predictor of 30-day mortality
Number of subjects: 184
Study 23973946 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel imaging group (Allura Clarity)
Number of subjects: 136
Study 23973946 — intervention group
Group type: COMPARATOR
Intervention: Reference group (Allura Xper)
Number of subjects: 136
Study 21356082 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic physical exercise
Number of subjects: 320
Study 21356082 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrients capsule (zinc 30 mg, selenium 70 μg, vitamin A 400 μg, alpha-tocopherol 30 mg, vitamin C 200 mg, niacin 100 mg)
Number of subjects: 320
Study 21356082 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined interventions (micronutrients and aerobic exercise)
Number of subjects: 320
Study 21356082 — intervention group
Group type: COMPARATOR
Intervention: Usual prenatal care and placebo (maltodextrin)
Number of subjects: 320
Study 19245076 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO) therapy
Number of subjects: 30
Study 19245076 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment in a hyperbaric chamber
Number of subjects: 30
Study 17978325 — intervention group
Group type: EXPERIMENTAL
Intervention: Real rTMS stimulation
Number of subjects: 127
Study 17978325 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 127
Study 15172903 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi‐institutional quality improvement collaborative (the 'Breakthrough Series')
Number of subjects: 9986
Study 15172903 — intervention group
Group type: COMPARATOR
Intervention: Control clinics
Number of subjects: 9986
Study 11672947 — intervention group
Group type: EXPERIMENTAL
Intervention: Ecstasy use
Number of subjects: 3274
Study 11672947 — intervention group
Group type: EXPERIMENTAL
Intervention: Polydrug use
Number of subjects: 3274
Study 11672947 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported symptoms
Number of subjects: 3274
Study 11672947 — intervention group
Group type: EXPERIMENTAL
Intervention: Social distribution of drug use
Number of subjects: 3274
Study 9039532 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose clarithromycin (1,000 mg or 750 mg b.i.d.)
Number of subjects: 45
Study 9039532 — intervention group
Group type: COMPARATOR
Intervention: Low-dose clarithromycin (1,000 mg or 750 mg q.d.)
Number of subjects: 45
Study 8176095 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg of atenolol once a day
Number of subjects: 18
Study 8176095 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg of controlled-release metoprolol once a day
Number of subjects: 18
Study 8176095 — intervention group
Group type: COMPARATOR
Intervention: Placebo once a day
Number of subjects: 18
Study 3283918 — intervention group
Group type: EXPERIMENTAL
Intervention: Al-Mg antacids (one tablet four times daily; acid-neutralizing capacity, 120 mmol/day) + pirenzepine (50 mg twice daily)
Number of subjects: 100
Study 3283918 — intervention group
Group type: COMPARATOR
Intervention: Al-Mg antacids (one tablet four times daily; acid-neutralizing capacity, 120 mmol/day) + pirenzepine placebo
Number of subjects: 100
Study 3283918 — intervention group
Group type: COMPARATOR
Intervention: Antacid placebo + pirenzepine (50 mg twice daily)
Number of subjects: 100
Study 3283918 — intervention group
Group type: COMPARATOR
Intervention: Antacid placebo + pirenzepine placebo
Number of subjects: 100
Study 3283918 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine (50 mg twice daily)
Number of subjects: 100
Study 3283918 — intervention group
Group type: COMPARATOR
Intervention: Antacid placebo
Number of subjects: 100
Study 29468315 — intervention group
Group type: EXPERIMENTAL
Intervention: SP base osteotomy
Number of subjects: 97
Study 29468315 — intervention group
Group type: COMPARATOR
Intervention: SP splitting osteotomy
Number of subjects: 97
Study 28069089 — intervention group
Group type: EXPERIMENTAL
Intervention: Test meal with 19-mg (all-E)-LYC from tomato paste
Number of subjects: 10
Study 28069089 — intervention group
Group type: COMPARATOR
Intervention: Test meal with 19-mg (all-E)-LYC from tomato paste plus 500-mg calcium carbonate
Number of subjects: 10
Study 25432920 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed incubator system
Number of subjects: 364
Study 25432920 — intervention group
Group type: COMPARATOR
Intervention: Conventional incubator system (control)
Number of subjects: 364
Study 23834402 — intervention group
Group type: EXPERIMENTAL
Intervention: Tafamidis
Number of subjects: 37
Study 21756382 — intervention group
Group type: EXPERIMENTAL
Intervention: Burdizzo clamp ablation of the testes (CAT)
Number of subjects: 19
Study 21756382 — intervention group
Group type: COMPARATOR
Intervention: Bilateral orchiectomy (BO)
Number of subjects: 19
Study 19629060 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (150 min/week of supervised gym‐ and home‐based moderate‐intensity aerobic exercise)
Number of subjects: 75
Study 19629060 — intervention group
Group type: COMPARATOR
Intervention: Usual care (maintain current physical activity level)
Number of subjects: 75
Study 16611682 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral saline hydration (1 g/10 kg of body weight/day for 2 days before the procedure)
Number of subjects: 312
Study 16611682 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous saline hydration (0.9% saline at a rate of 15 ml/kg for 6 h before the procedure)
Number of subjects: 312
Study 16611682 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous saline hydration plus theophylline (5 mg/kg per os 1 h before the procedure)
Number of subjects: 312
Study 16611682 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous saline hydration plus furosemide (3 mg/kg intravenously just after the procedure)
Number of subjects: 312
Study 16611682 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 312
Study 15478160 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucosamine sulfate (maximum 1,500 mg/day)
Number of subjects: 137
Study 15478160 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 137
Study 11505880 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose dexamethasone (100 mg stat, 16 mg every 6 hours for 48 hours)
Number of subjects: 40
Study 11505880 — intervention group
Group type: COMPARATOR
Intervention: Placebo (equivalent volumes to dexamethasone)
Number of subjects: 40
Study 11505880 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose dexamethasone
Number of subjects: 40
Study 11505880 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 8564394 — intervention group
Group type: EXPERIMENTAL
Intervention: Dispersed pattern of presented stereotype inconsistent information
Number of subjects: 0
Study 8564394 — intervention group
Group type: COMPARATOR
Intervention: Concentrated pattern of presented stereotype inconsistent information
Number of subjects: 0